BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Immuneering Corporation readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Immuneering Corporation's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05585320-2540@assetmemo.bio
DTSTAMP:20261121T005939Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atebimetinib: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Atebimetinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastati
 c Solid Tumors\nEstimated primary completion: June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/atebimetinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/atebimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562152-2540@assetmemo.bio
DTSTAMP:20261121T005939Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Atebimetinib: Phase 3 readout est. (NCT07562152)
DESCRIPTION:Atebimetinib\, phase 3\, Pancreatic Cancer.\nStudy: Atebimetini
 b + GnP as a First Line Treatment in Patients With Metastatic Pancreatic A
 denocarcinoma\nEstimated primary completion: June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/atebimetinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07562152
URL:https://assetmemo.bio/drug/atebimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946848-2540@assetmemo.bio
DTSTAMP:20261121T005939Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Atebimetinib: Phase 2 readout est. (NCT07946848)
DESCRIPTION:Atebimetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebi
 metinib in Participants With Advanced or Metastatic NSCLC.\nEstimated prim
 ary completion: May 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atebimetinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07946848
URL:https://assetmemo.bio/drug/atebimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
